The administration of a pharmacologically optimized kynureninase had substantial therapeutic effects when combined with approved checkpoint inhibitors or with a cancer vaccine for the treatment of 4T1 breast carcinoma, melanoma or CT26 colon carcinoma tumors (109). This evidence concerns the gene KYNU and melanoma.